|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||14.95 - 15.11|
|52 Week Range||11.00 - 23.75|
|Beta (3Y Monthly)||0.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2019 - Aug 16, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.43|
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Merus N.V. (MRUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...
The big shareholder groups in Merus N.V. (NASDAQ:MRUS) have power over the company. Institutions often own shares in...
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
UTRECHT, Netherlands, June 03, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
UTRECHT, The Netherlands, May 30, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
UTRECHT, The Netherlands, May 23, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
UTRECHT, Netherlands, May 20, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and preliminary efficacy of MCLA-145 for the treatment of patients with advanced solid tumors. “We are very pleased to announce the initiation of our Phase 1 trial for MCLA-145,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus.
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.